Business Context and Reporting Period
This Form 8-K reports the consummation of a business combination on July 31, 2024, between ARYA Sciences Acquisition Corp IV ("ARYA") and Adagio Medical, Inc. ("Adagio"). Following the closing, the combined entity operates as Adagio Medical Holdings, Inc. ("New Adagio") and trades on the Nasdaq under the symbol ADGM. Adagio is a medical device company developing Ultra-Low Temperature Cryoablation (ULTC) and Pulsed Field Cryoablation (PFCA) technologies for treating cardiac arrhythmias. The company has incurred net losses since inception and had not generated meaningful revenue prior to the transaction.
Key Financial Metrics
Financing and Liquidity:
- Total Financing Raised: Approximately $84.2 million, comprising funds from ARYA's trust account (net of redemptions), PIPE financing, and convertible security financing.
- PIPE Financing: Approximately $64.5 million committed by investors, including Perceptive Life Sciences Master Fund, Ltd. This included the conversion of $29.5 million in bridge financing notes and approximately $15.9 million in additional cash investment.
- Convertible Security Financing: $20.0 million in aggregate principal amount of 13% senior secured convertible notes ("New Adagio Convertible Notes") and 1.5 million Convert Warrants.
- Redemptions: Approximately $31.3 million paid to ARYA shareholders who exercised redemption rights (2,707,555 shares at ~$11.56/share).
- Pro Forma Cash: The unaudited pro forma balance sheet as of March 31, 2024, reflects combined cash and cash equivalents of approximately $40.3 million.
Historical Performance (Adagio):
- Revenue (3 months ended March 31, 2024): $26,000.
- Net Loss (3 months ended March 31, 2024): $8.0 million.
- Net Loss (Year ended Dec 31, 2023): $38.1 million.
- Accumulated Deficit (as of Dec 31, 2023): $135.2 million.
Capital Structure (Post-Closing):
- Shares Outstanding: 13,387,636 shares of New Adagio Common Stock.
- Warrants Outstanding: 7,528,727 Base Warrants and 670,000 Pre-Funded Warrants issued to PIPE investors; 1,500,000 Convert Warrants issued to Convert Investors.
- Debt: $20.0 million in New Adagio Convertible Notes (13% interest, maturing 3 years and 9 months post-closing).
Material Changes vs. Prior Period
The filing represents a fundamental structural change rather than a period-over-period operational comparison. Key changes include:
- Corporate Status: Transition from a private, pre-revenue development stage company to a publicly traded entity on Nasdaq.
- Capitalization: Significant dilution and restructuring of equity. All Adagio preferred stock and convertible notes (excluding bridge notes) were converted to common stock. ARYA Class A and B shares were converted to New Adagio Common Stock.
- Debt Restructuring: Existing Adagio bridge financing notes were converted into equity or new senior secured convertible notes. The SVB Term Loan was paid off at closing.
- Ownership Concentration: Perceptive Life Sciences Master Fund, Ltd. holds approximately 66.93% of the post-combination equity (including warrants), while the Sponsor (ARYA Sciences Holdings IV) holds approximately 17.58%.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy:
- Management expects to incur increasing costs as it devotes resources to product development and commercialization.
- Key milestones include data readouts from clinical trials (CRYOSURE-2, CRYOCURE-VT) and regulatory approvals in the U.S. (FDA) to complement existing EU CE Markings.
- The company anticipates continuing to operate at a loss for the foreseeable future until products are commercially launched and generate significant revenue.
Risks and Contingencies:
- Going Concern: Prior to the transaction, Adagio's management raised substantial doubt about its ability to continue as a going concern due to recurring losses and working capital deficiency. The transaction was intended to mitigate this.
- Regulatory Risk: Commercial success depends on obtaining U.S. regulatory approvals, which are not guaranteed.
- Dilution: Significant potential dilution exists from outstanding warrants (Base, Pre-Funded, and Convert Warrants) and equity incentive plans (2024 Equity Incentive Plan, Key Employee Plan, ESPP).
- Debt Covenants: The company must remain compliant with covenants related to the new 13% senior secured convertible notes.
Unusual Items:
- Transaction Costs: Approximately $10.0 million in transaction costs were incurred in connection with the business combination.
- Goodwill: Preliminary purchase price allocation recognized approximately $36.5 million in goodwill.
Investor Verification Checklist
- Capital Runway: Verify the actual cash balance post-closing and the projected burn rate to confirm the sufficiency of funds for the stated 2025 runway.
- Dilution Impact: Calculate the fully diluted share count including all warrants (Base, Pre-Funded, Convert) and options to understand the true ownership percentage of public shareholders.
- Debt Service: Review the terms of the $20 million 13% convertible notes, specifically the interest payment obligations (cash vs. compounding) and conversion mechanics.
- Regulatory Timeline: Confirm the status and expected dates for U.S. pivotal clinical trials and FDA submission for the iCLAS and vCLAS systems.
- Major Shareholder Control: Note that Perceptive Life Sciences Master Fund, Ltd. controls a majority stake (~67%), which may influence corporate governance and strategic decisions.
- Intangible Assets: Review the preliminary valuation of the $26.2 million in intangible assets (developed technology and IPR&D) and the associated amortization schedule.